Michael Blum brings more than 20 years of experience to Homology as a commercial leader in rare disease and biologics. He developed sales, marketing, market access and patient support services across multiple treatment areas, including Duchenne muscular dystrophy (DMD), Gaucher disease, mucopolysaccharidosis type II (MPS II), Prader Willi syndrome, hereditary angioedema, multiple sclerosis and psoriasis. Prior to Homology, Mr. Blum was the Head of Commercial Operations at Zafgen, Inc., where he was responsible for commercial strategy for rare disease and other treatment categories, including Type 2 diabetes. Mr. Blum was previously Head of Global Market Access at Sarepta Therapeutics, where he was responsible for the pipeline of DMD products in development. Mr. Blum was also the North American Business Lead at Shire, where he worked in the Rare Disease Business Unit. He was responsible for marketing, sales, reimbursement and patient services for three orphan drug treatments, including the launches of Elaprase, VPRIV and Firazyr. Mr. Blum holds a B.A. in English from the College of the Holy Cross and an M.B.A. from Babson College.